Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar developed by Biogen (NASDAQ:BIIB) as an intravenous therapy targeting ...

Jennifer Halchak; VP, IR; Organon & Co. Kevin Ali; Chief Executive Officer, Director; Organon & Co. Matthew Walsh; Chief Financial Officer, Senior Vice President; Or ...

The market is also upbeat about Organon’s recently acquired regulatory and commercial rights in the United States for TOFIDENCE from Biogen Inc. TOFIDENCE is the first approved tocilizumab ...

The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global ...

Tofidence is the first biosimilar approved ... These are activities that will enable Organon to redefine our appropriate sourcing strategy and move to fit-for-purpose supply chains while focusing ...